Laurus Investment Counsel Inc. Lowers Position in National Research Co. (NASDAQ:NRC)

Laurus Investment Counsel Inc. lessened its holdings in National Research Co. (NASDAQ:NRC) by 7.4% in the fourth quarter, Holdings Channel reports. The firm owned 20,690 shares of the company’s stock after selling 1,660 shares during the period. Laurus Investment Counsel Inc.’s holdings in National Research were worth $818,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of NRC. Portside Wealth Group LLC grew its stake in shares of National Research by 11.9% during the 4th quarter. Portside Wealth Group LLC now owns 5,238 shares of the company’s stock worth $207,000 after acquiring an additional 555 shares during the period. SG Americas Securities LLC bought a new position in National Research during the 4th quarter worth approximately $147,000. Vanguard Group Inc. grew its position in National Research by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 980,693 shares of the company’s stock worth $43,513,000 after acquiring an additional 10,454 shares during the last quarter. American Century Companies Inc. grew its position in National Research by 26.6% during the 3rd quarter. American Century Companies Inc. now owns 15,876 shares of the company’s stock worth $704,000 after acquiring an additional 3,332 shares during the last quarter. Finally, Deutsche Bank AG grew its position in National Research by 12.2% during the 3rd quarter. Deutsche Bank AG now owns 9,402 shares of the company’s stock worth $417,000 after acquiring an additional 1,025 shares during the last quarter. Institutional investors own 47.26% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, TheStreet lowered National Research from a “b-” rating to a “c+” rating in a research report on Thursday, January 11th.

National Research Trading Down 0.5 %

NASDAQ NRC opened at $39.40 on Thursday. The company has a quick ratio of 0.67, a current ratio of 0.67 and a debt-to-equity ratio of 0.60. National Research Co. has a twelve month low of $36.21 and a twelve month high of $47.25. The firm has a market capitalization of $939.69 million, a PE ratio of 31.52 and a beta of 0.42. The stock’s 50 day moving average is $39.56 and its 200 day moving average is $41.22.

National Research (NASDAQ:NRC) last announced its quarterly earnings data on Tuesday, February 13th. The company reported $0.36 earnings per share (EPS) for the quarter. The business had revenue of $38.00 million during the quarter. National Research had a return on equity of 47.79% and a net margin of 20.84%.

National Research Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Friday, March 29th will be paid a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date of this dividend is Wednesday, March 27th. National Research’s payout ratio is 38.40%.

Insider Buying and Selling at National Research

In other news, major shareholder Amandla Mk Trust sold 4,600 shares of the business’s stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $41.22, for a total value of $189,612.00. Following the completion of the transaction, the insider now owns 3,833,976 shares in the company, valued at $158,036,490.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.00% of the stock is owned by company insiders.

National Research Company Profile

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.